Kindex is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of metabolic disorders including Polycystic Ovary Syndrome (“PCOS”) and Nonalcoholic steatohepatitis (“NASH”).
Kindex leads the industry in its experience and understanding of a unique biological mechanism, theTAS2R (Bitter Taste Receptor) family of GPCRs
PCOS is a common endocrine disorder affecting between 5 and 10 % of women of reproductive age1. Many PCOS patients have a family history of diabetes or insulin resistance or a close relative who is similarly affected by androgen excess. Irregular ovulation in combination with excess androgens, excess hair growth (hirsutism), acne and obesity can all occur in women with PCOS. Women with PCOS are at greater risk for type 2 diabetes and cardiovascular disease and possibly hypertension and abnormal lipid levels.
The annual cost in 2005 in the USA for diagnosis and treatment of PCOS was $4.36 billion2.